See the DrugPatentWatch profile for polivy

After conducting a thorough research, I was unable to find specific information regarding the minimum age for Polivy (generic name: polatuzumab vedotin-piiq) clinical trials on the official Polivy website, FDA, or the manufacturer's (Genentech) website. However, I did find some relevant information on DrugPatentWatch.com that might help answer your question indirectly.

According to DrugPatentWatch.com [1]:

* Polivy was approved by the FDA in June 2019 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of aggressive non-Hodgkin lymphoma (NHL).
* Clinical trials for Polivy were conducted on adult patients with relapsed or refractory DLBCL.

While the exact minimum age for participation in these clinical trials is not specified, it is important to note that these trials were conducted on adult patients. Additionally, according to the American Cancer Society [2], NHL is more common in older adults, and it is rare in children and teens.

In summary, based on the available information, the minimum age for Polivy trials appears to be 18 years old or older, as the clinical trials were conducted on adult patients with relapsed or refractory DLBCL.

Sources:

* [1] DrugPatentWatch.com, "Polivy (polatuzumab vedotin-piiq) - Patent Expiration & Drug Sales", <https://www.drugpatentwatch.com/drugs/polivy>.
* [2] American Cancer Society, "Non-Hodgkin Lymphoma - Childhood", <https://www.cancer.org/cancer/non-hodgkin-lymphoma/children/about/what-is-childhood-nhl.html>.